Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial
The DOI matches its OpenAlex record.
Abstract
OBJECTIVE: To assess pairwise differences between placebo, unopposed estrogen, and each of three estrogen/progestin regimens on selected heart disease risk factors in healthy postmenopausal women. DESIGN: A 3-year, multicenter, randomized, double-blind, placebo-controlled trial. PARTICIPANTS: A total of 875 healthy postmenopausal women aged 45 to 64 years who had no known contraindication to hormone therapy. INTERVENTION: Participants were randomly assigned in equal numbers to the following groups: (1) placebo; (2) conjugated equine estrogen (CEE), 0.625 mg/d; (3) CEE, 0.625 mg/d plus cyclic medroxyprogesterone acetate (MPA), 10 mg/d for 12 d/mo; (4) CEE, 0.625 mg/d plus consecutive MPA, 2.5 mg/d; or (5) CEE, 0.625 mg/d plus cyclic micronized progesterone (MP), 200 mg/d for 12 d/mo. PRIMARY ENDPOINTS: Four endpoints were chosen to represent four biological systems related to the risk of cardiovascular disease: (1) high-density lipoprotein cholesterol (HDL-C), (2) systolic blood pressure, (3) serum insulin, and (4) fibrinogen. ANALYSIS: Analyses presented are by intention to treat. P values for primary endpoints are adjusted for multiple comparisons; 95% confidence intervals around estimated effects were calculated without this adjustment. RESULTS: Mean changes in HDL-C segregated treatment regimens into three statistically distinct groups: (1) placebo (decrease of 0.03 mmol/L [1.2 mg/dL]); (2) MPA regimens (increases of 0.03 to 0.04 mmol/L [1.2 to 1.6 mg/dL]); and (3) CEE with cyclic MP (increase of 0.11 mmol/L [4.1 mg/dL]) and CEE alone (increase of 0.14 mmol/L [5.6 mg/dL]). Active treatments decreased mean low-density lipoprotein cholesterol (0.37 to 0.46 mmol/L [14.5 to 17.7 mg/dL]) and increased mean triglyceride (0.13 to 0.15 mmol/L [11.4 to 13.7 mg/dL]) compared with placebo. Placebo was associated with a significantly greater increase in mean fibrinogen than any active treatment (0.10 g/L compared with -0.02 to 0.06 g/L); differences among active treatments were not significant. Systolic blood pressure increased and postchallenge insulin levels decreased during the trial, but neither varied significantly by treatment assignment. Compared with other active treatments, unopposed estrogen was associated with a significantly increased risk of adenomatous or atypical hyperplasia (34% vs 1%) and of hysterectomy (6% vs 1%). No other adverse effect differed by treatment assignment or hysterectomy status. CONCLUSIONS: Estrogen alone or in combination with a progestin improves lipoproteins and lowers fibrinogen levels without detectable effects on postchallenge insulin or blood pressure. Unopposed estrogen is the optimal regimen for elevation of HDL-C, but the high rate of endometrial hyperplasia restricts use to women without a uterus. In women with a uterus, CEE with cyclic MP has the most favorable effect on HDL-C and no excess risk of endometrial hyperplasia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The Protective Effects of Estrogen on the Cardiovascular System
Mendelsohn, M. E., & Karas, R. H. (1999) · New England Journal of Medicine · doi:10.1056/nejm199906103402306 · Cited by 3,103
Estrogen plus Progestin and the Risk of Coronary Heart Disease
Manson, J. E., Hsia, J., Johnson, K. C., Rossouw, J. E., Assaf, A. R., Lasser, N. L., Trevisan, M., Black, H. R., Heckbert, S. R., Detrano, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030808 · Cited by 2,065
Generation and reproductive phenotypes of mice lacking estrogen receptor β
Krege, J. H., Hodgin, J. B., Couse, J. F., Enmark, E., Warner, M., Mahler, J. F., Sar, M., Korach, K. S., Gustafsson, J.-Å., & Smithies, O. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15677 · Cited by 1,691
Delmas, P. D., Bjarnason, N. H., Mitlak, B. H., Ravoux, A.-C., Shah, A. S., Huster, W. J., Draper, M., & Christiansen, C. (1997) · New England Journal of Medicine · doi:10.1056/nejm199712043372301 · Cited by 1,637
Postmenopausal Estrogen and Progestin Use and the Risk of Cardiovascular Disease
Grodstein, F., Stampfer, M. J., Manson, J. E., Colditz, G. A., Willett, W. C., Rosner, B., Speizer, F. E., & Hennekens, C. H. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608153350701 · Cited by 1,305
Carey, R. M., Calhoun, D. A., Bakris, G. L., Brook, R. D., Daugherty, S. L., Dennison-Himmelfarb, C. R., Egan, B. M., Flack, J. M., Gidding, S. S., Judd, E., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000084 · Cited by 1,153
Triangulation in aetiological epidemiology
Lawlor, D. A., Tilling, K., & Davey Smith, G. (2017) · International Journal of Epidemiology · doi:10.1093/ije/dyw314 · Cited by 1,129
Selective Estrogen-Receptor Modulators — Mechanisms of Action and Application to Clinical Practice
Riggs, B. L., & Hartmann, L. C. (2003) · New England Journal of Medicine · doi:10.1056/nejmra022219 · Cited by 968
A Clinical Trial of Estrogen-Replacement Therapy after Ischemic Stroke
Viscoli, C. M., Brass, L. M., Kernan, W. N., Sarrel, P. M., Suissa, S., & Horwitz, R. I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010534 · Cited by 921
Treatment of symptoms of the menopause: an Endocrine Society Clinical Practice Guideline
Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J. V., & Santen, R. J. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2236 · Cited by 884
Schierbeck, L. L., Rejnmark, L., Tofteng, C. L., Stilgren, L., Eiken, P., Mosekilde, L., Kober, L., & Jensen, J.-E. B. (2012) · BMJ · doi:10.1136/bmj.e6409 · Cited by 747
Smoking and risk of myocardial infarction in women and men: longitudinal population study
Prescott, E., Hippe, M., Schnohr, P., Hein, H. O., & Vestbo, J. (1998) · BMJ · doi:10.1136/bmj.316.7137.1043 · Cited by 660
Increased Bone Mass as a Result of Estrogen Therapy in a Man with Aromatase Deficiency
Bilezikian, J. P., Morishima, A., Bell, J., & Grumbach, M. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808273390905 · Cited by 625
Hormone therapy for preventing cardiovascular disease in post-menopausal women
Boardman, H. M., Hartley, L., Eisinga, A., Main, C., Roqué i Figuls, M., Bonfill Cosp, X., Gabriel Sanchez, R., & Knight, B. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002229.pub4 · Cited by 612
for the Women’s Health Initiative Investigators, Margolis, K. L., Bonds, D. E., Rodabough, R. J., Tinker, L., Phillips, L. S., Allen, C., Bassford, T., Burke, G., Torrens, J., et al. (2004) · Diabetologia · doi:10.1007/s00125-004-1448-x · Cited by 599
HORMONE REPLACEMENT THERAPY, HEART DISEASE, AND OTHER CONSIDERATIONS
Barrett-Connor, E., & Grady, D. (1998) · Annual Review of Public Health · doi:10.1146/annurev.publhealth.19.1.55 · Cited by 590
Self-citationOral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes
MacLennan, A. H., Broadbent, J. L., Lester, S., & Moore, V. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002978.pub2 · Cited by 543
Protective actions of sex steroid hormones in Alzheimer’s disease
Pike, C. J., Carroll, J. C., Rosario, E. R., & Barron, A. M. (2009) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2009.04.015 · Cited by 522
Long-term hormone therapy for perimenopausal and postmenopausal women
Marjoribanks, J., Farquhar, C., Roberts, H., Lethaby, A., & Lee, J. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004143.pub5 · Cited by 424
Self-citationHormone replacement therapy: Fortnightly review
Barrett-Connor, E. (1998) · BMJ · doi:10.1136/bmj.317.7156.457 · Cited by 403
Self-citationHormone Therapy and the Progression of Coronary-Artery Atherosclerosis in Postmenopausal Women
Hodis, H. N., Mack, W. J., Azen, S. P., Lobo, R. A., Shoupe, D., Mahrer, P. R., Faxon, D. P., Cashin-Hemphill, L., Sanmarco, M. E., French, W. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030830 · Cited by 386
The Primary Prevention of Coronary Heart Disease in Women
Rich-Edwards, J. W., Manson, J. E., Hennekens, C. H., & Buring, J. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506293322607 · Cited by 382
Effects of Hormone-Replacement Therapy on Fibrinolysis in Postmenopausal Women
Koh, K. K., Mincemoyer, R., Bui, M. N., Csako, G., Pucino, F., Guetta, V., Waclawiw, M., & Cannon, R. O. (1997) · New England Journal of Medicine · doi:10.1056/nejm199703063361002 · Cited by 373
Self-citationThe Evaluation of Chest Pain in Women
Douglas, P. S., & Ginsburg, G. S. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605163342007 · Cited by 369
The Controversial History of Hormone Replacement Therapy
Cagnacci, A., & Venier, M. (2019) · Medicina · doi:10.3390/medicina55090602 · Cited by 298
Mortality associated with hormone replacement therapy in younger and older women: A meta-analysis
Salpeter, S. R., Walsh, J. M. E., Greyber, E., Ormiston, T. M., & Salpeter, E. E. (2004) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2004.30281.x · Cited by 292
Sherwin, B. B., & Henry, J. F. (2008) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2007.08.002 · Cited by 282
McSweeney, J. C., Rosenfeld, A. G., Abel, W. M., Braun, L. T., Burke, L. E., Daugherty, S. L., Fletcher, G. F., Gulati, M., Mehta, L. S., Pettey, C., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000381 · Cited by 263
Gambacciani, M., Ciaponi, M., Cappagli, B., De Simone, L., Orlandi, R., & Genazzani, A. R. (2001) · Maturitas · doi:10.1016/s0378-5122(01)00194-3 · Cited by 173
Evolution and Translation of Research Findings: From Bench to Where
Ioannidis, J. P. A. (2006) · PLoS Clinical Trials · doi:10.1371/journal.pctr.0010036 · Cited by 129
Sex hormone—binding globulin and insulin resistance in African-American women
Sherif, K., Kushner, H., & Falkner, B. E. (1998) · Metabolism · doi:10.1016/s0026-0495(98)90195-0 · Cited by 61
Wong, J. M., Kendall, C. W., Marchie, A., Liu, Z., Vidgen, E., Holmes, C., Jackson, C.-J., Josse, R. G., Pencharz, P. B., Rao, A. V., et al. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.017418 · Cited by 47
Effect of menopausal hormone therapy on components of the metabolic syndrome
Lovre, D., Lindsey, S. H., & Mauvais-Jarvis, F. (2017) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944716649358 · Cited by 44
Carr, M. C., Knopp, R. H., Brunzell, J. D., Wheeler, B. S., Zhu, X., Lakshmanan, M., Rosen, A. S., & Anderson, P. W. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1555 · Cited by 22
Turner syndrome through the lens of a gynaecologist
Jivraj, S., & Stillwell, S. (2021) · Post Reproductive Health · doi:10.1177/2053369120958593 · Cited by 5
Metadata
- Authors
- Miller, V. T., LaRosa, J. C., Barnabei, V. M., Kessler, C. M., Levin, G., Smith-Roth, A., Griffin, M. E., Stoy, D. B., Bush, T. L., Zacur, H. A., Foster, D., Anderson, J., McKenzie, A., Miller, S. R., Wood, P. D., Stefanick, M. L., Marcus, R., Akana, A., Heinrichs, W. L., Kirchner, C., O’Hanlan, K. A., Ruyle, M., Sheehan, M., Judd, H. L., Greendale, G. A., Bayalos, R., Lozano, K., Kawakami, K., Barrett‐Connor, E., Langer, R., Kritz‐Silverstein, D. C., Carrion-Petersen, M. L., Cavero, C., Schrott, H. G., Johnson, S. R., Feddersen, D., Krutzfeldt, D. L., Bénda, J., Pauerstein, C. J., Trabal, J. F., Schenken, R. S., Stern, M. P., Rodriguez-Sifuentes, M., Easton, C., Wells, H. B., Espeland, M. A., Howard, G., Byington, R. P., Legault, C., Shumaker, S. A., Hogan, P. E., Hire, D. G., Wasilauskas, C. H., James, M. K., Lane, K., Terrell, T., Reece, S., Pierce, J., Snow, M., Anthony, S., Mebane, I., Einhorn, P. T., Hunsberger, S., Waclawiw, M. A., Lippel, K., Lucas, D., Verter, J. I., Jackson, S., Kelaghan, J. W., Perlman, J. A., Wolf, P., McGowan, J., Gordon, S., Heyse, S. P., FRADKIN, J. E., Sherman, S., Page, L. B., Sorenson, A. W., Hulka, B. S., Brody, B. A., Burkman, R. T., Heaney, R. P., Krauss, R. M., Roberts, H., Wittes, J. T., Riggs, L. B., Moss, R., Albers, J. J., Marcovina, S. M., Fineberg, S. E., Tracy, R. P., Merino, M., Scully, R. E., LiVolsi, V. A., & Kessler, G.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 1995-01-18
- Volume
- 273
- Issue
- 3
- Pages
- 199
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W4254959959
- Cited by
- 601
- References
- 0
- FWCI
- 20.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.